Anterra Capital is the famous VC, which was founded in 2013. The leading representative office of defined VC is situated in the Amsterdam. The fund was located in Europe if to be more exact in The Netherlands.
This organization was formed by Adam Anders, Maarten Goossens, Philip Austin. Besides them, we counted 6 critical employees of this fund in our database.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Caribou Biosciences, Vestaron Corporation, Smartwyre. Among the most popular fund investment industries, there are Service Industry, GreenTech. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2016. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 39 percentage points more often commits exit comparing to other organizations.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Anterra Capital, startups are often financed by Unilever Ventures, Pangaea Ventures, Open Prairie. The meaningful sponsors for the fund in investment in the same round are Pangaea Ventures, Open Prairie, Cultivian Sandbox Ventures. In the next rounds fund is usually obtained by Wheatsheaf Group, Pangaea Ventures, Open Prairie.
Related Funds
Funds with similar focus
Fund Name | Location |
Cascadia Pacific | Kirkland, United States, Washington |
China Biomedical Fund Phase I | - |
Chuangke Accelerated Investment | China, Hangzhou, Zhejiang |
DRS | Chiyoda, Japan |
Gaz de France | - |
Maropost Ventures | - |
SCP Worldwide | New York, New York, United States |
SGI Venture Capital | Seoul, Seoul-t'ukpyolsi, South Korea |
Siena Holding | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Berkeley Yeast | $10M | 06 May 2023 | Oakland, California, United States | ||
Slingshot Biosciences | $11M | 06 Feb 2023 | Emeryville, California, United States | ||
Animol Discovery | $34M | 28 Jul 2022 | Boston, Massachusetts, United States | ||
Dalma. | $17M | 02 Jun 2022 | Paris, Ile-de-France, France | ||
Nom Nom Nom | $1M | 22 May 2022 | Amsterdam, Noord-Holland, The Netherlands | ||
Lollipop | $6M | 10 May 2022 | Chelmsford, Essex, United Kingdom | ||
BiomEdit | $40M | 14 Apr 2022 | Fishers, Indiana, United States | ||
Edge Animal Health | $10M | 01 Mar 2022 | New Jersey, Maryland, United States | ||
It's Fresh! | $5M | 25 Jan 2022 | Lichfield, England, United Kingdom |
– Smartwyre secured $10.5M in Series A funding.
– The funding was supported by High Alpha Capital, Anterra Capital, Fall Line Capital, Revolution’s Rise of the Rest fund and Cavallo Ventures.
– For the agricultural inputs industry, Smartwyre is the first platform to provide end-to-end insights from cost management to commercial pricing, improving industry profitability and preventing mismatches between production levels and the actual farmer demand.
– In 2021, companies delivering more than 35% of the agricultural inputs supplied to US farmers use Smartwyre’s platform to manage their product information, pricing or rebate operations.
– Slingshot Biosciences closed a $23m Series A financing.
– The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital.
– The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies.
– Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors.
– Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.
– Cell-derived products comprise the basis of important healthcare technologies worldwide.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Berkeley Yeast | $10M | 06 May 2023 | Oakland, California, United States | ||
Slingshot Biosciences | $11M | 06 Feb 2023 | Emeryville, California, United States | ||
Animol Discovery | $34M | 28 Jul 2022 | Boston, Massachusetts, United States | ||
Dalma. | $17M | 02 Jun 2022 | Paris, Ile-de-France, France | ||
Nom Nom Nom | $1M | 22 May 2022 | Amsterdam, Noord-Holland, The Netherlands | ||
Lollipop | $6M | 10 May 2022 | Chelmsford, Essex, United Kingdom | ||
BiomEdit | $40M | 14 Apr 2022 | Fishers, Indiana, United States | ||
Edge Animal Health | $10M | 01 Mar 2022 | New Jersey, Maryland, United States | ||
It's Fresh! | $5M | 25 Jan 2022 | Lichfield, England, United Kingdom |